Form4.ai tracks every SEC insider trade in real time. See every DYN insider filing with a free account — no card.
See every DYN insider filing — free account, no card.
Free accountDyne Therapeutics, Inc. (DYN) has 10 SEC Form 4 insider filings on record in the last 90 days. That includes 1 insider purchase totalling $40K, and 8 sales totalling $65.7M. Most recent filing: Oct. 22, 2026.
Open-market value, last 90 days
Form 4 filings by type, last 90 days
| Date | Insider | Trade | Value | Price since buy |
|---|---|---|---|---|
| Oct 22, 2026 SEC filing | Kerr Douglas Head of R&D and CMO | Grant / award | — | — |
| Oct 6, 2026 SEC filing | Posner Brian S Director | Bought | $40,000 | +8.1% 30D |
| Sep 8, 2026 SEC filing | Friedl-Naderer Johanna Chief Commercial Officer | Sold | $25,408 | — |
Create a free account to see all 10 DYN filings from the last 90 days. No card needed.
Create free accountWant DYN insider buys the moment they're filed, with Telegram alerts? Try Pro free for 7 days
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.